Pearls & Oy-sters: Relapse of anti-NMDA receptor encephalitis after prior first- and second-line immunotherapy

Sharon Chiang; Tanu Garg; Austin Hu; Hitha Amin; Alfredo Davalos-Balderas; Isabel Alfradique-Dunham; Corey E. Goldsmith

doi:10.1212/WNL.0000000000005517

Pearls & Oy-sters: Relapse of anti-NMDA receptor encephalitis after prior first- and second-line immunotherapy

Sharon Chiang, Tanu Garg, Austin Hu, Hitha Amin, Alfredo Davalos-Balderas, Isabel Alfradique-Dunham, Corey E. Goldsmith

Section of Movement Disorders

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Original language	English
Pages (from-to)	936-939
Number of pages	4
Journal	Neurology
Volume	90
Issue number	20
DOIs	https://doi.org/10.1212/WNL.0000000000005517
State	Published - 2018

Access to Document

10.1212/WNL.0000000000005517

Cite this

@article{f3815f60eca744999c6428e35146efc9,

title = "Pearls & Oy-sters: Relapse of anti-NMDA receptor encephalitis after prior first- and second-line immunotherapy",

author = "Sharon Chiang and Tanu Garg and Austin Hu and Hitha Amin and Alfredo Davalos-Balderas and Isabel Alfradique-Dunham and Goldsmith, {Corey E.}",

year = "2018",

doi = "10.1212/WNL.0000000000005517",

language = "English",

volume = "90",

pages = "936--939",

journal = "Neurology",

issn = "0028-3878",

number = "20",

}

TY - JOUR

T1 - Pearls & Oy-sters

T2 - Relapse of anti-NMDA receptor encephalitis after prior first- and second-line immunotherapy

AU - Chiang, Sharon

AU - Garg, Tanu

AU - Hu, Austin

AU - Amin, Hitha

AU - Davalos-Balderas, Alfredo

AU - Alfradique-Dunham, Isabel

AU - Goldsmith, Corey E.

PY - 2018

Y1 - 2018

UR - http://www.scopus.com/inward/record.url?scp=85064083288&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000005517

DO - 10.1212/WNL.0000000000005517

M3 - Article

C2 - 29759996

AN - SCOPUS:85064083288

SN - 0028-3878

VL - 90

SP - 936

EP - 939

JO - Neurology

JF - Neurology

IS - 20

ER -

Pearls & Oy-sters: Relapse of anti-NMDA receptor encephalitis after prior first- and second-line immunotherapy

Access to Document

Other files and links

Cite this